rituximab,ibrutinib,Bendamustine
biogen,roche,novartis,janssen,abbvie
['improve', 'rituximab', 'shine']
coming to you live from #asco22: new data on 1l ibrutinib + bendamustine + rituximab with rituximab maintenance in older patients with mcl! primary results from the phase iii shine study demonstrated mpfs of 6.7 years, a significant improvement compared to standard chemo 
Real time, on-demand personalized cancer education and support through our online educational platform